Cite
Rutsaert S, Steens JM, Gineste P, et al. Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study. J Virus Erad. 2019;5(1):10-22
Rutsaert, S., Steens, J. M., Gineste, P., Cole, B., Kint, S., Barrett, P. N., Tazi, J., Scherrer, D., Ehrlich, H. J., & Vandekerckhove, L. (2019). Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study. Journal of virus eradication, 5(1), 10-22.
Rutsaert, Sofie, et al. "Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study." Journal of virus eradication vol. 5,1 (2019): 10-22.
Rutsaert S, Steens JM, Gineste P, Cole B, Kint S, Barrett PN, Tazi J, Scherrer D, Ehrlich HJ, Vandekerckhove L. Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study. J Virus Erad. 2019 Jan 01;5(1):10-22. PMID: 30800421; PMCID: PMC6362909.
Copy
Download .nbib